Showing all 6 results
Darifenacin Prolonged Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix Prolonged-Release Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute physical stability of the controlled-release polymer.
Active Ingredient Strength Primary Clinical Function Darifenacin Hydrobromide USP/Ph.Eur.
(Equivalent to Darifenacin base)7.5 mg (PR) The Standard Titration & Geriatric Anchor: The definitive, highly efficacious starting and maintenance dose utilized for the vast majority of patients to control OAB symptoms with minimal side effects. Darifenacin Hydrobromide USP/Ph.Eur. 15 mg (PR) The Severe Refractory Macrodose: High-efficacy therapeutic payload utilized strictly for patients who require greater symptom relief and have demonstrated high tolerability to the 7.5 mg dose. Excipients Hypromellose (HPMC) / Dibasic Calcium Phosphate / Magnesium Stearate / Polyethylene Glycol / Titanium Dioxide / Premium Polymeric Film Hydrophilic PR Matrix / Diluent / Lubricant / Plasticizer / Opaque Film (Engineered specifically utilizing high-viscosity Hypromellose. Upon contact with gastrointestinal fluids, the tablet hydrates to form a thick, gelatinous outer layer that strictly controls the diffusion of the highly soluble hydrobromide salt over a 24-hour period) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urological dispensing regimens).
Desvenlafaxine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix Extended-Release Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical and physical stability of the controlled-release polymer.
Active Ingredient Strength Primary Clinical Function Desvenlafaxine Succinate USP/Ph.Eur.
(Equivalent to Desvenlafaxine base)50 mg (ER) The Global Therapeutic Standard: The definitive, highly efficacious starting and maintenance dose utilized for the vast majority of patients suffering from Major Depressive Disorder. Desvenlafaxine Succinate USP/Ph.Eur. 100 mg (ER) The Severe Refractory Macrodose: High-efficacy therapeutic payload utilized strictly for severe, treatment-resistant depression where maximum norepinephrine reuptake inhibition is required. Excipients Hypromellose (HPMC) / Microcrystalline Cellulose / Talc / Magnesium Stearate / Premium Polymeric Film Hydrophilic ER Matrix / Diluent / Glidant / Lubricant / Film-Coating (Engineered specifically utilizing high-viscosity Hypromellose. Upon contact with gastric fluid, the tablet forms a thick, gelatinous outer layer that slowly erodes over 24 hours, guaranteeing a smooth, flat pharmacokinetic curve to prevent violent nausea and serotonin spikes) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day psychiatric dispensing regimens).
Epalrestat Sustained Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Photostable SR Matrix Tablet, packed exclusively in highly secure, light-blocking Alu-Alu blister strips to ensure the absolute chemical survival of the intensely photolabile molecule.
Active Ingredient Strength Primary Clinical Function Epalrestat USP/Ph.Eur. 150 mg (SR) The Global Diabetology Standard: The definitive macrodose engineered for 24-hour continuous aldose reductase suppression, dramatically improving patient adherence over standard 50mg TID dosing. Excipients Hypromellose (HPMC) / Microcrystalline Cellulose / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Titanium-Dioxide Film Rate-Controlling Polymer / Diluent / Glidant / Lubricant / UV-Barrier Film (Engineered utilizing elite viscosity-grade HPMC to form a gel-matrix in the gut for sustained drug release, finished with a heavy, opaque film-coat to act as an absolute UV/Light barrier) *Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict 3-to-6 month chronic diabetic dispensing regimens).
Isoxsuprine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Immediate-Release or Sustained-Release Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the active pharmaceutical ingredient.
Active Ingredient Strength Primary Clinical Function Isoxsuprine Hydrochloride USP/Ph.Eur. 10 mg (IR) Acute Titration Standard: Immediate-release base unit used for the rapid initiation of therapy or carefully titrated maintenance in sensitive patients. Isoxsuprine Hydrochloride USP/Ph.Eur. 40 mg (SR) Obstetrics Maintenance Standard: High-efficacy, slow-release matrix designed specifically to provide 12-hour continuous tocolysis, vastly improving maternal compliance and protecting the cardiovascular system. Excipients Hypromellose (HPMC) / Microcrystalline Cellulose / Lactose Monohydrate / Colloidal Silicon Dioxide / Magnesium Stearate ER Polymer / Diluent / Binder / Glidant / Lubricant (Engineered specifically utilizing premium Hypromellose matrices in the 40mg variant to form a robust hydrogel that slowly erodes in the gastrointestinal tract, ensuring steady-state plasma levels) *Pack Sizes: 10×10 Blisters (Optimized specifically for strict obstetric and chronic vascular dispensing regimens).
Lithium Carbonate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute physical stability of the controlled-release polymers.
Active Ingredient Strength Primary Clinical Function Lithium Carbonate USP/Ph.Eur. 300 mg (IR) Acute Mania Standard: Immediate-release base unit used for the rapid, aggressive titration of serum lithium levels during an active, severe manic episode. Lithium Carbonate USP/Ph.Eur. 400 mg / 450 mg (ER/SR) Global Maintenance Standard: Extended-release therapy designed to flatten the pharmacokinetic curve, preventing toxic blood spikes and minimizing severe hand tremors and nausea during lifelong maintenance therapy. Excipients Hypromellose (HPMC) / Microcrystalline Cellulose / Sodium Starch Glycolate / Magnesium Stearate / Premium Opadry Film Hydrophilic ER Polymer / Diluent / Disintegrant / Lubricant (Engineered specifically using high-shear wet granulation to form a highly reliable, slow-eroding matrix that trickles the elemental lithium into the bloodstream over 12 hours) *Pack Sizes: Bottles of 100 or 10×10 Blisters (Optimized specifically for strict, massive-volume lifelong psychiatric dispensing regimens).
Mirabegron Extended-Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix ER Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute physical stability of the extended-release polymers.
Active Ingredient Strength Primary Clinical Function Mirabegron Ph.Eur./USP 25 mg (ER) Initiation / Renal Standard: Base therapeutic unit for assessing patient tolerance and for use in patients with severe renal or hepatic impairment. Mirabegron Ph.Eur./USP 50 mg (ER) Global Urology Standard: High-efficacy adult maintenance therapy for maximum suppression of urge urinary incontinence and detrusor overactivity. Excipients Polyethylene Oxide / Hypromellose (HPMC) / Butylated Hydroxytoluene (BHT) / Magnesium Stearate / Premium Opadry Film Swellable ER Polymer / Hydrophilic Matrix Base / Antioxidant / Lubricant (Engineered specifically to form an impenetrable, slow-eroding gel matrix in the GI tract, strictly metering the release of the active ingredient over 24 hours) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urology dispensing regimens).
